Benitec Biopharma Ltd ADR

Benitec Biopharma Inc. is a clinical-stage biotechnology company focused on developing novel genetic medicines. Its DNA-directed RNA interference platform, Silence and Replace, combines RNA interference with gene therapy to create medicines that aim to silence disease-causing genes while delivering wildtype replacement genes after a single administration. The company is developing BB-301, an AAV-based gene therapy designed to silence the disease-causing gene for the treatment of oculopharyngeal muscular dystrophy related dysphagia. Benitec Biopharma Inc. is headquartered in Hayward, California.